Story perspectives
FDA Approves Monthly Injection Uzedy for Bipolar I Treatment
10/15/2025
28 3
1 of 1
Story summary
- The FDA approved Uzedy (risperidone) as a once-monthly extended-release injection for maintenance treatment of bipolar I disorder in adults.
- The approval aims to address treatment gaps and improve adherence for bipolar I disorder with severe symptoms.
- Clinical studies showed the injection prolonged time to relapse versus placebo.
- Adverse events included injection site nodules and weight gain.
- Teva's Chris Fox stated Uzedy builds on its success in treating schizophrenia.
